Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Correspondence] Men B: lack of coverage or vaccine failure?

In the UK, a substantial reduction of cases of serogroup B (MenB) meningococcal disease in infants is anticipated following the introduction of Bexsero (GlaxoSmithKline) into the infant immunisation schedule. This vaccine is not, however, a panacea. Strain coverage is estimated at 88% for UK MenB strains,1 allowing for the possibility of MenB disease in Bexsero-immunised individuals due to strains not covered by the vaccine (appendix).